| Identification | Back Directory | [Name]
lithium O-acetylsalicylate | [CAS]
552-98-7 | [Synonyms]
Aspirin lithium
lithium acetylsalicylate
lithium O-acetylsalicylate
2-Acetoxybenzoic acid lithium salt | [EINECS(EC#)]
209-029-5 | [Molecular Formula]
C9H9LiO4 | [MOL File]
552-98-7.mol | [Molecular Weight]
188.11 |
| Hazard Information | Back Directory | [Uses]
Aspirin (Acetylsalicylic Acid) lithium is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin lithium induces apoptosis. Aspirin lithium inhibits the activation of NF-κB. Aspirin lithium also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis[1][2][3][4][5][6]. | [in vivo]
Aspirin lithium (5-150 mg/kg, PO, once) shows significant antipyretic activity in adult yeast-fevered male rats[7]. | Animal Model: | Male albino Charles River rats (200-250 g, 8 animals/group, fever was induced by 20 ml/kg of a 20 % aqueous suspension of brewer’s yeast which was injected SC in the back below the nape of the neck)[7] | | Dosage: | 5, 25, 50, 100 and 150 mg/kg | | Administration: | PO, once | | Result: | Produced a statistically significant decrease of 0.23 ℃ at 15 min post-drug at the dose of 150 mg/kg. Antipyretic effect gradually increased in magnitude until a peak effect of 1.96 ℃ was reached at 120 min post-drug. The ED50 of aspirin was found to be 10.3 mg/kg with confidence limits of 1.8-23.0 mg/kg. The antipyretic response to aspirin is dependent on the dose of the compound administered. |
| [IC 50]
COX-1; COX-2 | [References]
[1] Mitchell JA, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and induciblecyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7. DOI:10.1073/pnas.90.24.11693
[2] Blanco FJ, et al. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. PMID:10381057
[3] Wu KK, et al. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12. DOI:10.1055/s-2003-40668
[4] Kopp E, et al. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994 Aug 12;265(5174):956-9. DOI:10.1126/science.8052854
[5] Burch JW, et al. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978 Feb;61(2):314-9. DOI:10.1172/JCI108941
[6] Elwood PC, et al. Aspirin, salicylates, and cancer. Lancet. 2009 Apr 11;373(9671):1301-9. DOI:10.1016/S0140-6736(09)60243-9
[7] Loux JJ, DePalma PD, Yankell SL. Antipyretic testing of aspirin in rats. Toxicol Appl Pharmacol. 1972 Aug;22(4):672-5. DOI:10.1016/0041-008x(72)90295-5 |
|
|